Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.

@article{Rotstein1999RandomizedPT,
  title={Randomized placebo-controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. The Canadian Fluconazole Prophylaxis Study Group.},
  author={Coleman Rotstein and Eric James Bow and Mich{\'e}l Laverdi{\`e}re and Stratis Ioannou and Derek Carr and Nima Moghaddam},
  journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America},
  year={1999},
  volume={28 2},
  pages={331-40}
}
A randomized, double-blind trial comparing oral fluconazole (400 mg daily) with placebo as prophylaxis for adult patients receiving intensive cytotoxic therapy for acute leukemia or autologous bone marrow transplantation was conducted in 14 Canadian university-affiliated hospitals. Although fluconazole prophylaxis did not obviate the need for parenteral antifungal therapy compared with placebo (81 [57%] of 141 vs. 67 [50%] of 133, respectively), its use resulted in fewer superficial fungal… CONTINUE READING
71 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 71 extracted citations

Similar Papers

Loading similar papers…